Tumor Predisposition Genes: Penetrance, Prevalence, and Estimation of Risk

Value of the Information & Strength of the Argument

The presentation provides valuable insights into the application of genomic ascertainment to cancer predisposition genes, using large-scale biobank data to refine penetrance and prevalence estimates. The argumentation is solid, based on published studies and ongoing research, with clear explanations of methodology and limitations. The speaker effectively uses non-cancer examples to illustrate key concepts, making the argument accessible. However, some data are preliminary and not yet peer-reviewed, and the speaker acknowledges the need for further validation.

The title accurately reflects the content, which focuses on penetrance, prevalence, and risk estimation in tumor predisposition genes, with a strong emphasis on genomic ascertainment.

8/10

The talk is given by a senior investigator at the NCI with extensive experience in cancer genetics, and it presents data from large-scale genomic ascertainment studies, including peer-reviewed publications and ongoing research. The methods are clearly described, and the speaker acknowledges limitations and biases. However, some data are from unpublished work, and the presentation is an expert opinion rather than a systematic review.

Markers derived by PSI from the transcript: the creator did not define chapters.

• 02:00Introduction of Dr. Douglas Stewart and the topic of tumor predisposition genes.
• 05:00Explanation of phenotype-first vs. genome-first approaches.
• 10:00Discussion of the Geisinger MyCode biobank and its advantages.
• 15:00Presentation of Marfan syndrome and Noonan syndrome genomic ascertainment findings.
• 20:00Introduction to CHEK2 and the genome-first study using Geisinger and UK Biobank.
• 25:00Presentation of CHEK2 risk estimates and comparison with traditional studies.
• 30:00Discussion of PALB2 and preliminary findings from genomic ascertainment.

• RASopathy Study at NCI — Mentioned as an ongoing study for referral of RASopathy cases.
• Inherited Cancer Registry on Bluesky — Social media link provided in the description.
• Inherited Cancer Registry on LinkedIn — Social media link provided in the description.

• Genome-first approach in clinical genetics — Supports the concept of genome-first approach discussed in the talk.
• UK Biobank — Data source used in the studies presented.
• ClinVar — Used for variant classification in the studies.

• Traditional phenotype-first studies — The talk contrasts genome-first findings with traditional phenotype-first studies, which often report higher penetrance and more severe phenotypes.